Tissue-specific cell-free DNA degradation quantifies circulating tumor DNA burden
Profiling of circulating tumor DNA (ctDNA) may offer a non-invasive approach to monitor disease progression. Here, we developed a quantitative method, exploiting local tissue-specific cell-free DNA (cfDNA) degradation patterns, that accurately estimates ctDNA burden independent of genomic aberrations. Nucleosome-dependent cfDNA degradation at promoters and first exon-intron junctions was strongly associated with differential transcriptional activity in tumors and blood. A quantitative model, based on just 6 regulatory regions, could accurately predict ctDNA levels in colorectal cancer patients. Strikingly, a model restricted to blood-specific regulatory regions could predict ctDNA levels across both colorectal and breast cancer patients.
- Type: Other
- Archiver: EGA European Genome-Phenome Archive
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
|EGAD00001006419||Illumina HiSeq 4000||12|
|EGAD00001006420||Illumina HiSeq 4000||10|
|EGAD00001006421||Illumina HiSeq 4000||29|
|EGAD00001008352||Illumina HiSeq 4000||7|
Tissue-specific cell-free DNA degradation quantifies circulating tumor DNA burden.
Nat Commun 12: 2021 2229